Inovio Pharmaceuticals (NASDAQ:INO) Shares Cross Above 200 Day Moving Average – Here’s What Happened

by · The Markets Daily

Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.05 and traded as high as $2.08. Inovio Pharmaceuticals shares last traded at $2.07, with a volume of 991,382 shares changing hands.

Analysts Set New Price Targets

INO has been the subject of a number of research analyst reports. UBS Group reaffirmed an “overweight” rating on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. Citigroup reissued a “market outperform” rating on shares of Inovio Pharmaceuticals in a report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research report on Monday, December 1st. Piper Sandler reiterated an “overweight” rating and set a $6.00 price target (up from $5.00) on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th. Finally, Zacks Research downgraded Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $9.00.

Read Our Latest Stock Analysis on INO

Inovio Pharmaceuticals Price Performance

The company has a market cap of $138.13 million, a PE ratio of -0.80 and a beta of 1.54. The stock has a fifty day moving average price of $2.22 and a 200-day moving average price of $2.05.

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.07. On average, equities analysts anticipate that Inovio Pharmaceuticals, Inc. will post -4.23 earnings per share for the current year.

Institutional Trading of Inovio Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd boosted its holdings in shares of Inovio Pharmaceuticals by 26.7% during the first quarter. XTX Topco Ltd now owns 66,169 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 13,939 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Inovio Pharmaceuticals by 38.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 98,495 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 27,429 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Inovio Pharmaceuticals during the 1st quarter valued at $168,000. Freedom Investment Management Inc. purchased a new position in shares of Inovio Pharmaceuticals during the 1st quarter valued at $31,000. Finally, Nomura Holdings Inc. acquired a new position in shares of Inovio Pharmaceuticals in the first quarter worth $28,000. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

(Get Free Report)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Featured Stories